drugset / Trial / NCT00442754

Dendritic Cells in Lung Cancer

NCT00442754 ↗

Phase 2 Completed 50 enrolled Herlev Hospital University of Copenhagen · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Vaccination with autologous dendritic cells pulsed with allogeneic melanoma cell lysate (MelCancerVac) in combination with the Cox-2 inhibitor of celecoxib for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). Adjuvant Aldara cream will be used as adjuvant for induction of inflammation at the injection site, and the lymphocyte growth factor of interleukin-2 (IL-2) will be given as s.c. injection. The treatment aims at boosting the patient's specific immune system against the cancer cells.

Timeline

Start
2006-12
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject MelCancerVac Vaccine — Subcutaneous